Microbiome & Chronic Diseases

Evidence Based Medicine
Sign in
≡ List 

Disease ⇒ Melanoma ⇒ Cancer {40000152}

Record Keys



Initialisation date:
Other Terms:
Malignant melanoma


Meta Information

MedDra ID:[  ]
MedDra Level:[  ]
ICD:[  ]
Dermatology, Oncology
Zone:[  ]
Mechanism:[  ]


[  ]

References Notes

[  ]

Shared Reference Notes

  • [1.1
    - Patients with an unfavorable gut microbiome (e.g., low diversity and high relative abundance of Bacteroidales) have impaired systemic and anti-tumor immune responses mediated by limited intratumoral lymphoid and myeloid infiltration and weakened antigen presentation capacity.
    - The gut microbiome may modulate responses to anti PD-1 immunotherapy in melanoma patients.
    - Patients with a favorable gut microbiome (e.g., high diversity and abundance of Ruminococcaceae/Faecalibacterium) have enhanced systemic and anti-tumor immune responses mediated by increased antigen presentation, and improved effector T cell function in the periphery and the tumor microenvironment.
  • [1.2
    - FMT and anti–PD-1 changed the gut microbiome and reprogrammed the tumor microenvironment to overcome resistance to anti–PD-1 in a subset of PD-1 advanced melanoma.
  • [1.3
    -Bifidobacterium emerged as strongly associated with T cell response, and consistently, oral administration of a cocktail of Bifidobacterium species combined with an anti-PD-L1 antibody nearly abolished the melanoma growth.
    - Bifidobacterium longum, Collinsella aerofaciens, and Enterococcus faecium was associated with anti-PD1 efficacy in metastatic melanoma patients. (2)
  • [1.4
    - Higher dietary fiber > improved progression-free survival in 128 patients on immune checkpoint blockade (ICB) treatment, with the most pronounced benefit observed in patients with sufficient dietary fiber intake and no probiotic use.